Granules India Reports Fourth Quarter And Annual Results
ECONOMY & POLICY

Granules India Reports Fourth Quarter And Annual Results

All monetary figures are in Rs million (mn). Granules India reported results for the fourth quarter and fiscal year ended 31 March 2026. Fourth quarter revenue from operations was Rs 14,706 mn, up 23 per cent year on year, with earnings before interest, tax, depreciation and amortisation of Rs 3,521 mn, up 40 per cent, and profit before tax before exceptional items at Rs 2,464 mn, up 48 per cent; net profit was Rs 2,016 mn, up 33 per cent.\n\nNorth America accounted for 72 per cent of fourth quarter revenue and Europe for 17 per cent. Finished dosages contributed 73 per cent, active pharmaceutical ingredients 13 per cent, pharmaceutical formulation intermediates 9 per cent and Peptides CDMO 5 per cent. Return on capital employed rose to 17.6 per cent in FY26 from 16.6 per cent, and net debt declined to Rs 4,021 mn, down Rs 3,040 mn year on year, leaving net debt to EBITDA at 0.34 times.\n\nOn a yearly basis, consolidated revenue was Rs 53,656 mn, up 20 per cent, with EBITDA of Rs 11,851 mn, up 25 per cent and an EBITDA margin of 22 per cent. Reported net profit for FY26 was Rs 5,950 mn, up 19 per cent year on year, and profit before tax before exceptional items was Rs 7,950 mn.\n\nThe chairman and managing director attributed the results to portfolio expansion, disciplined execution and progress on regulatory, compliance and sustainability initiatives, and noted improved earnings quality alongside advancement in complex generics and the Peptides CDMO platform. Granules India is a vertically integrated pharmaceutical company operating across active pharmaceutical ingredients, pharmaceutical formulation intermediates, finished dosages and Peptides CDMO, and serves more than 300 customers in over 80 countries. The group operates 10 manufacturing facilities, including 7 in India, 2 in the United States and 1 in Switzerland, and holds approvals from multiple regulators.

All monetary figures are in Rs million (mn). Granules India reported results for the fourth quarter and fiscal year ended 31 March 2026. Fourth quarter revenue from operations was Rs 14,706 mn, up 23 per cent year on year, with earnings before interest, tax, depreciation and amortisation of Rs 3,521 mn, up 40 per cent, and profit before tax before exceptional items at Rs 2,464 mn, up 48 per cent; net profit was Rs 2,016 mn, up 33 per cent.\n\nNorth America accounted for 72 per cent of fourth quarter revenue and Europe for 17 per cent. Finished dosages contributed 73 per cent, active pharmaceutical ingredients 13 per cent, pharmaceutical formulation intermediates 9 per cent and Peptides CDMO 5 per cent. Return on capital employed rose to 17.6 per cent in FY26 from 16.6 per cent, and net debt declined to Rs 4,021 mn, down Rs 3,040 mn year on year, leaving net debt to EBITDA at 0.34 times.\n\nOn a yearly basis, consolidated revenue was Rs 53,656 mn, up 20 per cent, with EBITDA of Rs 11,851 mn, up 25 per cent and an EBITDA margin of 22 per cent. Reported net profit for FY26 was Rs 5,950 mn, up 19 per cent year on year, and profit before tax before exceptional items was Rs 7,950 mn.\n\nThe chairman and managing director attributed the results to portfolio expansion, disciplined execution and progress on regulatory, compliance and sustainability initiatives, and noted improved earnings quality alongside advancement in complex generics and the Peptides CDMO platform. Granules India is a vertically integrated pharmaceutical company operating across active pharmaceutical ingredients, pharmaceutical formulation intermediates, finished dosages and Peptides CDMO, and serves more than 300 customers in over 80 countries. The group operates 10 manufacturing facilities, including 7 in India, 2 in the United States and 1 in Switzerland, and holds approvals from multiple regulators.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code